![]() |
|
|
Vol. 62, Issue 5, 1011-1026, November 2002
Section of Paediatric Clinical Pharmacology, Toxicology & Experimental Therapeutics, Departments of Paediatrics, Pharmacology & Toxicology, and Medicine, Faculty of Medicine & Dentistry, University
of Western Ontario, Ontario, Canada (T.M., D.H., M.J.R.); and Child
Health Research Institute - Robarts Research Institute Children's
Hospital of Western Ontario London, Ontario, Canada (L.D., S.G.F.,
M.J.R.)
Adverse drug reactions are a major problem complicating medical
therapy. The pathogenesis of many severe adverse drug reactions, notably hypersensitivity reactions, is poorly understood. The sulfonamides are associated with severe hypersensitivity reactions. The
initial pathogenesis seems to be caused by bioactivation of the parent
drug to a reactive intermediate and subsequent propagation by the
immune system. The determinants of the immune response are not known.
We explored the formation of sulfonamide haptens in Molt-3 and HEPA
1C1C7 cells after incubation with sulfamethoxazole (SMX), the
hydroxylamine of sulfamethoxazole (SMX-HA), or the nitroso of
sulfamethoxazole (SMX-NO). Haptenation was demonstrated with SMX-HA and
SMX-NO but not SMX; this occurred at concentrations below that
associated with toxicity (significant haptenation was seen at 25 to 50 µM). Thus, haptenation occurred presumably onto viable cells.
Haptenation occurred rapidly; haptenation of cell surface proteins was
demonstrated within 5 min. This did not occur indiscriminately;
confocal microscopy demonstrated haptenation onto specific sites on the
cell membrane. We found that haptenation was significantly inhibited by
thiols and other antioxidants (p < 0.05).
Sulfonamide-specific haptens were rapidly internalized by what seemed
to be a caveolae-dependent process. It seems that sulfonamide reactive
metabolites haptenated specific cell surface proteins that are rapidly
internalized. Understanding the specific protein target(s) for
haptenation and how these haptens are processed will be important in
understanding the immune mediation of sulfonamide hypersensitivity
adverse drug reactions.
This article has been cited by other articles:
![]() |
L. Cheng, B. J. Stewart, Q. You, D. R. Petersen, J. A. Ware, J. R. Piccotti, T. T. Kawabata, and C. Ju Covalent Binding of the Nitroso Metabolite of Sulfamethoxazole Is Important in Induction of Drug-Specific T-Cell Responses in Vivo Mol. Pharmacol., June 1, 2008; 73(6): 1769 - 1775. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Sanderson, D. J. Naisbitt, J. Farrell, C. A. Ashby, M. J. Tucker, M. J. Rieder, M. Pirmohamed, S. E. Clarke, and B. K. Park Sulfamethoxazole and Its Metabolite Nitroso Sulfamethoxazole Stimulate Dendritic Cell Costimulatory Signaling J. Immunol., May 1, 2007; 178(9): 5533 - 5542. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Roychowdhury, P. M. Vyas, and C. K. Svensson Formation and Uptake of Arylhydroxylamine-Haptenated Proteins in Human Dendritic Cells Drug Metab. Dispos., April 1, 2007; 35(4): 676 - 681. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Lin, M J. Tucker, and M. J Rieder Increased Adverse Drug Reactions to Antimicrobials and Anticonvulsants in Patients with HIV Infection Ann. Pharmacother., September 1, 2006; 40(9): 1594 - 1601. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Vyas, S. Roychowdhury, and C. K. Svensson ROLE OF HUMAN CYCLOOXYGENASE-2 IN THE BIOACTIVATION OF DAPSONE AND SULFAMETHOXAZOLE Drug Metab. Dispos., January 1, 2006; 34(1): 16 - 18. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Roychowdhury, P. M. Vyas, T. P. Reilly, A. A. Gaspari, and C. K. Svensson Characterization of the Formation and Localization of Sulfamethoxazole and Dapsone-Associated Drug-Protein Adducts in Human Epidermal Keratinocytes J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 43 - 52. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Farrell, D. J. Naisbitt, N. S. Drummond, J. P. H. Depta, F. J. Vilar, M. Pirmohamed, and B. K. Park Characterization of Sulfamethoxazole and Sulfamethoxazole Metabolite-Specific T-Cell Responses in Animals and Humans J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 229 - 237. [Abstract] [Full Text] [PDF] |
||||